New cocktail aims to crush High-Risk myeloma

NCT ID NCT03104842

Ongoing Disease control Sponsor: Universitätsklinikum Hamburg-Eppendorf Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of four drugs—isatuximab, carfilzomib, lenalidomide, and dexamethasone—in 246 people newly diagnosed with high-risk multiple myeloma. The goal is to see if this intensive regimen can make the cancer undetectable (MRD-negative) and keep it under control. Participants receive the drugs in three phases: induction, consolidation, and maintenance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab, carfilzomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this combination could offer a more effective way to control high-risk multiple myeloma and achieve deeper remission.
What could go wrong: This is a mid-stage trial with no control group, so results are preliminary. The drugs have significant side effects, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Asklepios Altona

Hamburg, Germany
Campus Benjamin Franklin Charite Berlin

Berlin, Germany
Johanniter-Krankenhaus Bonn

Bonn, 53113, Germany
Kliniken Maria Hilf GmbH, Klinik für Hämatologie, Onkologie und Gastroenterologie

Mönchengladbach, 41063, Germany
Klinikum Osnabrück

Osnabrück, Germany
Philipps-Universität Marburg

Marburg, 35032, Germany
St. Antonius Hospital

Eschweiler, Germany
Städt. Kliniken Bielefeld Klinikum Mitte

Bielefeld, Germany
Uniklinik Köln

Cologne, Germany
Uniklinikum Chemnitz

Chemnitz, Germany
University Hospital Hamburg Eppendorf

Hamburg, Germany
University Hospital Heidelberg

Heidelberg, Germany
Universitätsklinikum Essen

Essen, Germany
Universitätsklinikum Tuebingen

Tübingen, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, D-55131, Germany
Vivantes Am Urban

Berlin, 10967, Germany
Vivantes Klinikum Neukölln

Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.